{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:39:17Z","timestamp":1792651157084,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ejpb.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T06:30:18Z","timestamp":1363847418000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention"],"prefix":"10.1016","volume":"86","author":[{"given":"Christophe","family":"Duret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Merlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Wauthoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thami","family":"Sebti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Vanderbist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Amighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2013.03.005_b0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2013.03.005_b0010","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Florl","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2013.03.005_b0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","article-title":"Aerosolized delivery of antifungal agents","volume":"4","author":"Le","year":"2010","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.ejpb.2013.03.005_b0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejpb.2010.01.011","article-title":"Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats","volume":"75","author":"Yang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2013.03.005_b0025","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-012-0779-4","article-title":"New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis","author":"Duret","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.03.005_b0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2012.03.002","article-title":"Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties","volume":"428","author":"Duret","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2013.03.005_b0035","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/jps.20053","article-title":"Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1\u201334) from rat lungs","volume":"93","author":"Codrons","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.03.005_b0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejpb.2012.04.004","article-title":"In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice","volume":"81","author":"Duret","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2013.03.005_b0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0168-3659(03)00033-6","article-title":"Comparison of dissolution profiles of Ibuprofen pellets","volume":"89","author":"Costa","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2013.03.005_b0050","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.2147\/IJN.S34091","article-title":"New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis","volume":"7","author":"Duret","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2013.03.005_b0055","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/03639040802516491","article-title":"The characterization and comparison of spray-dried mannitol samples","volume":"35","author":"Hulse","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2013.03.005_b0060","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jps.20644","article-title":"Analytical techniques for quantification of amorphous\/crystalline phases in pharmaceutical solids","volume":"95","author":"Shah","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.03.005_b0065","first-page":"1209","article-title":"Dry powder inhaler formulation","volume":"50","author":"Telko","year":"2005","journal-title":"Respir. Care"},{"key":"10.1016\/j.ejpb.2013.03.005_b0070","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2013.03.005_b0075","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/ajrcmb.16.3.9070608","article-title":"Expression and localization of CYP3A4 and CYP3A5 in human lung","volume":"16","author":"Anttila","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejpb.2013.03.005_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03639040903092319","article-title":"Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties","volume":"36","author":"Tolman","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2013.03.005_b0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jinf.2007.01.014","article-title":"Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis","volume":"55","author":"Alvarez","year":"2007","journal-title":"J. Infect."},{"key":"10.1016\/j.ejpb.2013.03.005_b0090","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1128\/AAC.50.4.1552-1554.2006","article-title":"In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis","volume":"50","author":"Hoeben","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2013.03.005_b0095","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1378\/chest.115.5.1424","article-title":"Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study","volume":"115","author":"Osaki","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2013.03.005_b0100","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/js980403l","article-title":"Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs","volume":"88","author":"Serajuddin","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.03.005_b0105","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1007516718048","article-title":"What is the true solubility advantage for amorphous pharmaceuticals?","volume":"17","author":"Hancock","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.03.005_b0110","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1002\/jps.23306","article-title":"Evaluation of drug supersaturation by thermodynamic and kinetic approaches for the prediction of oral absorbability in amorphous pharmaceuticals","volume":"101","author":"Ozaki","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2013.03.005_b0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2013.03.005_b0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0005-2736(81)90570-8","article-title":"Effect of dimyristoyl phosphatidylcholine on intact erythrocytes. Release of spectrin-free vesicles without ATP depletion","volume":"641","author":"Ott","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2013.03.005_b0125","first-page":"362","article-title":"Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells","volume":"284","author":"Lindmark","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2013.03.005_b0130","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ejpb.2012.04.019","article-title":"Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice","volume":"81","author":"Beinborn","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2013.03.005_b0135","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2005.06.009","article-title":"Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages","volume":"107","author":"Zhou","year":"2005","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T21:30:32Z","timestamp":1539811832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641113000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0939641113000921"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.03.005","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}